''Biotech, domestic healthcare manufacturing and food staples will still have export demand and so the market will naturally favour these. ''
Are you serious Kickst@rter
Do you honestly think the market will favour pre revenue - highly speculative biotechs in phase 11 as safe havens
Biotechs with revenues and actual commercialised drugs - like the big billion dollar pharmas
DYOR
